Cassava Sciences Inc (SAVA)
$26.48
Performance
- $26.02$31.23$26.48
1.74%
Downside
Day's Volatility :16.67%
Upside
15.2%
- $8.79$42.20$26.48
66.81%
Downside
52 Weeks Volatility :79.17%
Upside
37.25%
Returns
| Period | Cassava Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -14.44% | -7.3% | 0.0% |
6 Months | 21.47% | -0.5% | 0.0% |
1 Year | 24.03% | 10.5% | 0.0% |
3 Years | -49.63% | 8.8% | -24.0% |
Highlights
Market Capitalization | 1.5B |
Book Value | $3.47 |
Earnings Per Share (EPS) | -1.38 |
Wall Street Target Price | 116.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -45.6% |
Return On Equity TTM | -10.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -68.0M |
EBITDA | -143.3M |
Diluted Eps TTM | -1.38 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.24 |
EPS Estimate Next Year | -0.65 |
EPS Estimate Current Quarter | -0.88 |
EPS Estimate Next Quarter | -0.99 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 338.07%
Technicals Summary
Sell
Neutral
Buy
Cassava Sciences Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cassava Sciences Inc | -5.39% | 21.47% | 24.03% | -49.63% | 1778.01% |
 Regeneron Pharmaceuticals, Inc. | -21.61% | -24.74% | -7.55% | 13.66% | 101.19% |
 Biontech Se | 1.94% | 14.27% | 14.47% | -63.37% | 445.2% |
 Alnylam Pharmaceuticals, Inc. | -16.95% | 63.94% | 50.31% | 30.85% | 117.83% |
 Vertex Pharmaceuticals Incorporated | -4.06% | 0.04% | 27.74% | 141.35% | 101.98% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cassava Sciences Inc | NA | NA | NA | -1.24 | -0.11 | -0.46 | NA | 3.47 |
Regeneron Pharmaceuticals, Inc. | 18.41 | 18.41 | 1.11 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.53 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cassava Sciences Inc | Buy | $1.5B | 1778.01% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.8B | 101.19% | 18.41 | 33.61% |
Biontech Se | Buy | $25.9B | 445.2% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.8B | 117.83% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.0B | 101.98% | 32.84 | -4.51% |
Insights on Cassava Sciences Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.3% return, outperforming this stock by 25.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 30.9% return, outperforming this stock by 80.5%
Institutional Holdings
BlackRock Inc
6.71%Vanguard Group Inc
5.26%State Street Corp
2.45%Geode Capital Management, LLC
2.02%Susquehanna International Group, LLP
1.44%Gallacher Capital Management LLC
1.21%
Company Information
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
Organization | Cassava Sciences Inc |
Employees | 29 |
CEO | Mr. Eric J. Schoen |
Industry | Pharmaceuticals: Other |
Discover More
Arc Document Solutions Inc
$26.48
-17.71%
Exscientia Plc
$26.48
-17.71%
Tmt Acquisition Corp
$26.48
-17.71%
Ngl Energy Partners Lp
$26.48
-17.71%
Ondas Holdings Inc
$26.48
-17.71%
Sonida Senior Living Inc.
$26.48
-17.71%
Vitesse Energy Inc.
$26.48
-17.71%
Spdr Marketaxess Investment Grade 400 Corp Bd Etf
$26.48
-17.71%
Blackrock High Yield Bond Etf
$26.48
-17.71%